HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study.

Date publication

janvier 2023

Journal

Breast cancer (Tokyo, Japan)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent , Pr COUTANT Charles , Dr LADOIRE Sylvain , Dr BILLA Oumar , Dr DESMOULINS Isabelle

Tous les auteurs :
Kada Mohammed S, Billa O, Ladoire S, Jankowski C, Desmoulins I, Poillot ML, Coutant C, Beltjens F, Dabakuyo S, Arnould L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36715845

Résumé

HER2-positive (HER2 +) invasive lobular breast cancer (ILC) is rare and poorly characterised. In particular, patient outcomes compared to those associated with HER2 + invasive ductal cancer (IDC) and HER2-negative (HER2 -) ILC, as well as the benefits of anti-HER2 therapy, are not well established.

Mots clés

Anti-HER2 therapy, Breast cancer, HER2-positive lobular carcinoma, Registry, Survival

Référence

Breast Cancer. 2023 01 30;: